Field of Science

Does modern day college and graduate education in chemistry sacrifice rigor for flexibility?

This is what I love about blogging; it's the classic "one thing leads to another" device. The previous discussion on the paucity of thermodynamics in college coursework led to a more general and important exchange in the comments section that basically asked: Are we sacrificing rigor for flexibility by giving students too much freedom to pick and choose their courses?

The following sentiments (or variations thereof) were expressed:

- There should be a core curriculum for chemistry students that exposes them to mandatory courses in general, organic and physical chemistry at the very least. These requirements seems to be more widespread among physics departments. To my knowledge, Caltech is one of the few schools with a general core curriculum for all science majors. How many other schools have this?

- Part of the lack of exposure to important topics in grad school results from emphasizing research at the cost of coursework. And this is related to a more widespread sentiment of woe: it's become all too easy to get a PhD, partly because of the curse of academia that encourages one to become a glorified technician at the cost of instilling creative scientific thought. The belief is that many professors (and there's many exceptions) would rather produce well-trained manual laborers who contribute to the Grant and Paper Production Factory than independent scientific thinkers who can assimilate ideas from diverse scientific fields. You shouldn't really get a Ph.D. just for putting in 80-hour weeks.

We need to hold students to higher standards, but I think this is not going to happen until the publish-or-perish culture is fundamentally transformed and the movers and shakers of academic research take a hard look at what they are doing to their graduate students.

- Many textbooks are mired in the age-old, classical presentation of thermodynamics that emphasizes Carnot cycles and Maxwell relations much more than any semi-quantative feel for the operation of thermodynamic in practical chemical and biological systems. We are just not doing a good job communicating the real-world importance of topics like thermodynamics; add to this students who are not going to study something if it's not required and we are in a real bind.

- Physical organic chemistry - the one discipline that can naturally build bridges between physical and organic chemistry - is disappearing from the curriculum. Those who intellectually matured in its heyday were naturally exposed to thermodynamics and kinetics. Graduate students in organic chemistry shouldn't be able to get away with just synthesis and spectroscopy courses.

- Matt who, unlike most of us armchair philosophers, is a live professor at an actual research institution, makes the point that we should do an outstanding job of emphasizing thermodynamics in the freshman general chemistry class. We should do such a good job that students should always be able to connect those concepts to anything else that they study later. As Matt recommends, we could include the more qualitative important real-life applications of thermodynamics (and not just to antiquated heat engines) like those in drug discovery in this gen chem class.

All great points in my opinion. I have strong feelings about all this myself, but I have not done any detailed study of college curricula so my opinions are mostly anecdotal. Feel free to chime in with actual data or more opinions in the comments section.

Who's afraid of Big Bad Thermodynamics?

George Whitesides, in a trademark outfit.
In a talk at Northeastern University yesterday, George Whitesides asked the students in the audience if they had ever studied thermodynamics. Not a single hand went up.

Even accounting for the fact that some students might have been reluctant to flag themselves in a large audience, I find this staggering, especially if these students are planning to go into basic drug discovery research. But I can’t completely blame them. I happened to take one (mandatory) thermodynamics and one (non-mandatory) basic statistical mechanics class in college and was exposed to thermodynamics in graduate school through my work on conformational equilibria and NMR. But most of my fellow graduate students in organic and biochemistry had little inkling of thermodynamics; it certainly wasn't a part of their standard intellectual toolkit.

The problem’s made worse by misunderstandings about thermodynamics that seem to linger in students’ heads even later in their career. These misunderstandings stem from a larger rift between organic and physical chemistry; the latter is supposed to be highly mathematical and abstract and rather irrelevant to the former. This is in spite of the overwhelming importance of concepts from p-chem in classical physical organic chemistry. Sadly, classical physical organic chemistry itself is disappearing from the college and grad school curriculum, and an argument in favor of emphasizing thermodynamics is also a plug for not letting physical organic chemistry become a relic of the past. No other topic gives you as good a basic feel for structure, function and reactivity in organic chemistry.

But coming back to thermodynamics, this impression that many students have about thermodynamics being all about Maxwell relations and Carnot cycles and virial theorems is rather misleading. It’s not that these things are not important, it’s just that that’s not the kind of thermodynamics Whitesides was talking about when he was talking about drug discovery. Thermodynamics in drug discovery is often much less complicated than bonafide textbook thermodynamics. And it’s of foundational importance in the field since at its core, drug discovery is about understanding molecular recognition which is completely a thermodynamic phenomenon governed by free energy.

For a drug designer, the key thermodynamic circus to understand is the interplay between G, H, and S as manifested in the classic equation ∆G = ∆H – T∆S. It’s key to get a feel for how opposing values of H and S can lead to the same value of G, since this is at the heart of protein-drug recognition. It’s also important to know the different features of water, protein and solvent that contribute to changes in these parameters. Probably the most important thermodynamic effect that drug designers need to be aware of is the hydrophobic effect. They need to know that the hydrophobic effect is largely an entropic effect arising from the release of bound waters, although as Whitesides has himself demonstrated, reality can be more complicated. But the fact is that we simply cannot understand water without thermodynamics, and we cannot understand drug action without understanding water.

Also paramount is to understand the relationship between thermodynamics and kinetics, something that again benefits from studying reactions under thermodynamic and kinetic control and things like the Curtin-Hammet principle in classical physical organic chemistry. It’s crucial to know the difference between thermodynamic and kinetic stability, especially when one is dealing with small molecule and protein conformations. Finally, it’s enormously valuable to have a feel for a few key numbers, foremost among which may be the relationship between equilibrium constant and free energy; knowing this tells you for instance that it takes only a difference of 1.8 kcal/mol of free energy between two conformers to almost completely shift the conformational equilibrium on to the side of the more stable one. And when that difference is 3 kcal/mol, the higher-energy conformation is all gone, well beyond the detection limits of techniques like NMR. Speaking of which, a good understanding of thermodynamics also tells you why it’s incorrect to rely on average NMR data to tease apart the details of multiple conformations in solution.

All this knowledge about thermodynamics is ingrained more easily than complicated mathematical derivations of configuration integrals in free-energy perturbation theory. Students need to realize that the thermodynamics that they need to tackle drug discovery is a semi-quantitative blend of ideas relying much more on a rough feel for numbers and competing entropic and enthalpic effects. This kind of feel can lead to some very useful insights, for instance regarding relationships between G, H and S in the evolution of new drugs.

It’s time to incorporate this more general thermodynamics outlook in drug discovery classes and even in regular chemistry classes. It’s simple enough to be taught to undergraduates and bypasses the more sophisticated and intimidating ideas of statistical mechanics.

In yesterday’s conference, the chairman had the last laugh. Half-jokingly he emphasized that Northeastern’s chemistry course is ACS certified, which means that one semester of p-chem and thermodynamics are mandatory. Apparently Harvard’s is not. To which Whitesides replied that he can guarantee that you will find students at Harvard who are also not familiar with thermodynamics.

Whitesides's appeal to give pharmaceutical scientists-in-training a firm grounding in thermodynamics applies across the board. On top of Plato’s Academy there was rumored to be a sign which said “Let no one ignorant of geometry enter”. Perhaps one can make a similar case for thermodynamics in the pharmaceutical industry?

Note: 

I have often written about thermodynamics in drug design on my blog. A few potentially useful posts:


Some useful references:

George Whitesides - Designing ligands to bind tightly to proteins (book chapter PDF): Includes much of the material from Whitesides's talk.
Jonathan Chaires - Calorimetry and Thermodynamics in Drug Design.

Live blogging the Northeastern Drug Discovery conference

So I figured that since I am attending the drug discovery conference at Northeastern University I might as well jot down a few thoughts about the talks.

Leroy Hood: Institute for Systems Biology (Seattle).


Lots of optimism, which is usually the case with systems biology talks; being able to distinguish "wellness" genes from "disease" genes for everybody in about ten years, being able to map all disease-related biomarkers from blood analysis etc. But there were some interesting tidbits:


- Noise - especially biological noise - cannot be handled by traditional machine learning approaches. Signal to noise ratio is very low especially when picking biomarkers.

- SysBio can help pharma pick targets (which it is increasingly getting worse at).
- Cost can be minimized in optimal cases; eg. FDA approved Herceptin specific for 20% of patients in only 40-patient sample (Genentech). 
- Descriptive and graphical models can be enormously useful; in fact complexity often precludes mathematical modeling.
- Example of prions injected into mouse: expression of 33% genes changed. Biological noise can be “subtracted” by judiciously picking strains that get rid of one effect and preserve others.

My own take on systems biology has always been that, while it is likely to become quite significant at some point:


a. It's going to take longer than we think.

b. Separating signal from noise and honing in on the handful of approaches which will be robust and meaningful is going to give us a lot of grief. This will likely be Darwinian selection at its best.


Patricia Hurter (Vertex): Formulation

For people like me in discovery, formulation is a whole new world. Compaction, rolling, powder flow, force-response curves; engineers would feel right at home with these concepts, and in fact they do. And of course, you don’t talk about anything less than 25 kilograms.


Eric Olson (Vertex): Cystic Fibrosis

- Most common mutation is F508del (targets 88% of patients)

- Two potential drugs; potentiators (for restoring function) and correctors (for localizing protein from ER to membrane surface).
- However, only potentiators needed for G551D mutation (targets 4% of patients). Ivacaftor increases probability of channel being open; more beating cilia (nice video).
- Development challenges: little CF expertise, limited patient pop, no defined preclinical and regulatory path, outcomes for proof-of-concept and phase 3 not well established for mechanism-of-action.

I thought that the development of Vertex's CF drugs is a model example of charting out drug development in a novel, unexplored area.



Arun Ghosh (Purdue): Darunavir

From a medicinal chemistry standpoint this was probably the most impressive. Ghosh is one of the very few academic scientists to have a drug (Darunavir) named after them. He described the evolution of Darunavir from the key idea of targeting the backbone of HIV protease; the belief was that while side-chains are different between HIV mutants, the backbone stays constant and therefore compound binding to the backbone would be effective against resistant strains. 

This idea turned out to be remarkably productive, and Ghosh described a series of studies that just kept on improving potencies against virtually any mutant HIV strain that the biologists threw at the compound. It was a medicinal chemist’s dream; there was a wealth of crystal structure data, compounds routinely turned out to have picomolar potencies, and almost every single modification that the chemists designed worked exactly as expected. Some of this success was of course good luck, but that’s something that’s usually a given in drug discovery. Darunavir and its analogs got fast-track FDA approval against HIV strains that had failed to respond against every other medication. Ghosh’s study was a powerful reminder that the right kind of design principal can lead to exceptional success, even against a target that's been beaten to death.

George Whitesides (Harvard): Challenges

Interesting talk by Whitesides. A pretty laid back speaker. The first half was a general rumination on the state of pharma and drug discovery ("the current model of capitalism is not working"; "the FDA has become unreasonable"; "if the best we can do in cancer is to invent a drug that gives someone 3 extra months with a lot of side effects, then we are doing something wrong").

The second half concerned his work on the hydrophobic effect. The papers deal with ligand binding to carbonic anhydrase. Basically he found out that the so-called entropic signature of the hydrophobic effect (an increase in entropy from release of bound water molecules) is more complicated.

A few notes:


- Designing drugs is hard because we are robust, multi multiplexed complex systems.
- Cost of healthcare in the US is ~17% of GDP: also, no correlation between health cost and quality, as evidenced by low standing of US.
- Quoted Anna Karenina’s happy and unhappy families; has something to do with drug development. Every successful drug has its success in common, unsuccessful drugs are unsuccessful in their own way.
- Pharmaceutical crisis has nothing to with per se with science, everything to do with costs.

Finally, he made an important point: biochemists have always done experiments in dilute phosphate buffer. Interior of cell is anything but.

Favorite quote, regarding the limitations of animal models: "Whatever else you may think of me, I am not a large, hairless mouse”

Book review: Benoit Mandelbrot's "The Fractalist"

"My life", says Benoit Mandelbrot in the introduction to his memoir, "reminds me of that fairy tale in which the hero finds a hitherto unseen thread, and as he unravels the thread it leads him to unimaginable and unknown wonders". Mandelbrot not only found those wonders, but bequeathed to us the thread which will continue to lead us to more wondrous discoveries.

Mandelbrot was one of those chosen few scientists in history who are generalists, people whose ideas impact a vast landscape of fields. A maverick in the best sense of the term, he even went one step further and created his own field of fractal geometry. In a nutshell, he developed a "theory of roughness", and the fractals which represent this roughness are now household names, even making it into "Jurassic Park". Today fractals are known to manifest themselves in a staggering range of phenomena; the rhythms of the heart, the distribution of galaxies, market fluctuations, the rise and fall of species populations, the shapes of blood vessels, earthquakes, and the weather. Before Mandelbrot scientists liked to deal with smooth averages and equilibria, assuming that the outliers, the anomalies, the sudden jumps from normalcy were rare and could be ignored. Mandelbrot proved that they can't and found methods to tame them and bring them into the mainstream. His insights into this new view of nature effected minor and major revolutions in fields as diverse as economics, astronomy, physiology and fluid dynamics. More than almost any other thinker he was responsible for teaching natural and social scientists to model the world as it is rather than the abstraction which they want it to be.

In this memoir Mandelbrot describes his immensely eventful and somewhat haphazard journey to these revelations. The volume is quirky, charming, wide-ranging, often lingering on self-similar themes, much like his fractals. It is divided into three parts. The first deals with family history and childhood influences. The second deals with a peripatetic, broad scientific education. The third details Mandelbrot's great moments of discovery, the ones he calls "Keplerian moments" in homage to the great astronomer who realized the power of abstract mathematical notions to illuminate reality.

Mandelbrot grew up in a Lithuanian family first in Warsaw and then in France. He came from an educated and intellectually alert household. His most formative influences were his garment-maker father and dentist mother and especially his mathematician uncle Szolem. The parents had acquired great reserves of tenacity, having been uprooted from one place to another at least six times because of the depression. Szolem had toured the great centers of European mathematics and knew quite a few famous mathematicians himself. Mandelbrot grew up steeped in the mathematical beauty and folklore which Szolem vividly imparted to him. A dominant theme in the household was self-improvement, constantly challenging oneself to do better. This theme served Benoit well.

Mandelbrot's early years were marked by the rise of Nazism. After the fall of France his family fled Paris, taking refuge in the south of France before the country was liberated. There were dangerous moments, like his father narrowly escaping a strafing and Benoit and his cousin being interrogated by the Vichy police. After the war Mandelbrot studied at the prestigious École Polytechnique. At this point his central character started to reveal itself; an intellectual restless that inspired forays into diverse fields, a thirst for knowledge that would take him to many corners of the globe, a tendency to question orthodox wisdom and most importantly, an unwillingness to be a specialist. All these traits would turn out to be paramount in his future discoveries. Throughout his life Mandelbrot was known as a sometimes cantankerous and difficult person, but while there is a trace of these qualities in his memoir, most of the volume is generous in acknowledging the influence of family, friends, colleagues and institutions.

His intellectual restlessness led him across the Atlantic to major centers of scientific research including Caltech, MIT and the Institute for Advanced Study in Princeton, where he was the last postdoc of the great mathematician John von Neumann. Part of the joy of the book comes from Mandelbrot's accounts of encounters with a veritable who's who of late twentieth century science including von Neumann, Oppenheimer, Wiener, Feynman, Chomsky and Stephen Jay Gould. A particularly memorable incident has him flabbergasted by a penetrating comment from an audience member and Oppenheimer and von Neumann coming to his defense to explain his ideas even better than he could. At all these institutions Mandelbrot worked on a remarkable variety of problems, from aircraft design to linguistics, and acquired a rare, extremely broad education that would serve him in good stead.

As he explains, the trajectory of Mandebrot's life was irrevocably changed when his uncle Szolem introduced him to a law named Zipf's Law that deals with the frequencies of words in various languages. Mandelbrot discovered that Zipf's law led to some counterintuitive and universal results that could only be explained by non-standard distributions; this was when he discovered the high prevalence of what many had previous considered to be "rare" events. His work in this area as well as some preliminary work in economics led him to a highly productive position at IBM. Mandelbrot describes IBM's remarkable scientific culture that allowed scientists like him to pursue unfettered basic scientific research; sadly that culture has now all but vanished in many organizations. During this time he stayed in touch with academia, giving seminars at many leading universities. Ironically, it was Mandelbrot's lack of specialization that made universities reluctant to hire him; implicitly, his experience is also a critique of an academic system that discourages broad thinkers and generalists. The difficulty of pinning down an unconventional thinker like Mandelbrot is reflected in the fact that Chicago found his interests too spread out while Harvard thought them too narrow!

But IBM was more than happy to support his multiple intellectual forays and in addition to his own explorations he also has accounts of IBM's pioneering work in software and graphics design. It was while at IBM that Mandelbrot discovered what he is most famous for - fractals. As the book recounts, the work arose partly from analyzing price and market fluctuations. Mandelbrot was struck by the uncanny similarity of disparate price and income curves and realized that the equilibrium model that economists were relying for decades was of little use in analyzing real world jumps which tended to be much more frequent than normal distributions would indicate. In a set of stunning and sweeping intellectual insights engendered by his broad scientific background, Mandelbrot realized that the math underlying an astonishing range of phenomena, from economic fluctuations to geographic coastlines, is the same. His work in this area was seminal by any standard, but it was not adopted by economists partly because they found it difficult to use and partly because the field was entrenched in established ideas from equilibrium models. It was only in the 1980s that his insights became accepted into the mainstream, and the global recession in 2008 and the shocks to the economy have soundly validated his fractal fluctuation models. Outliers are not so rare after all, and as Nassim Taleb has documented, their impact can be tremendous and unpredictable. The parts of the book charting the road leading to fractals are fascinating and clearly detail the advantage of having a broad scientific education.

In spite of the lukewarm reception by economists Mandelbrot persevered along his general line of thinking, and in the late 1970s he discovered the iconic Mandelbrot set which made him a household name. Starting from an almost laughably simple formula, one quickly generates what has been called the most complex object in mathematics. The stunning geometry of the set today dots everything from murals to coffee mugs and there are hundreds of websites on which you can generate the set and examine it. Zooming in on the picture reveals a thick and endlessly complex jungle of self-similar geometric shapes and convolutions; one can gaze at this mesmerizing creature for hours.

Mandelbrot retired from IBM in the 80s and his career culminated in his appointment as the Sterling professor at Yale University. His eventful journey, from Warsaw to New Haven, holds many key lessons for us. He taught us to celebrate diversity and broad interests in an era of specialization. He shifted the focus of scientists from the idealized experiments of their laboratories to the messy world of reality. And he made it clear that many of the most penetrating insights into nature like fractals emerge from asking simple questions and exploring the obvious; What's the length of Britain's coastline? What's the shape of clouds? How does the heart beat?

It is hard to think of a twentieth century thinker whose ideas have influenced so many disciplines, and the fruits of Mandelbrot's labors promise continuing revelations long after his death in 2010. His memoir makes a resounding case for the virtues of indulging in, in Feynman's words, "perfectly reasonable deviations from the beaten track".


Image

How to run a world-class lab

One of this year's Nobel laureates in physics, Serge Haroche, has a few words of wisdom for fostering a good research environment.

Our experiments could only have succeeded with the reliable financial support provided by the institutions that govern our laboratory, supplemented by international agencies inside and outside Europe. European mobility programs also opened our laboratory to foreign visitors, bringing expertise and scientific culture to complement our own. During this long adventure in the micro-world, my colleagues and I have retained the freedom to choose our path without having to justify it with the promise of possible applications. 



Unfortunately, the environment from which I benefited is less likely to be found by young scientists embarking on research now, whether in France or elsewhere in Europe. Scarcity of resources due to the economic crisis, combined with the requirement to find scientific solutions to practical problems of health, energy and the environment, tend to favour short-term, goal-oriented projects over long-term basic research. Scientists have to describe in advance all their research steps, to detail milestones and to account for all changes in direction. This approach, if extended too far, is not only detrimental to curiosity-driven research. It is also counterproductive for applied research, as most practical devices come from breakthroughs in basic research and would never have been developed out of the blue.

Haroche’s quip about short-termism being bad even for applied research is especially worth noting, since applied research is supposedly what short-termism seeks to encourage. The point is that the path of science is almost always unexpected and complex, and most applied research is the illegitimate albeit charming and often spectacularly successful offspring of blue-sky basic research. Neglect of this foundation is one major flaw I see with the whole concept of “translational medicine” which seems to lack an accurate appreciation of the haphazard way in which basic scientific principles have actually translated to practical medical therapies. Unless we know the underlying biology of disease, which even now is quite complex for us to grasp, it’s not going to be possible to have scientists sit in a room and think up treatments for Alzheimer’s disease and diabetes.
On a related note, an article in Nature explores the phenomenal success of the MRC’s Laboratory of Molecular Biology at Cambridge which has produced 9 Nobel Laureates, the latest one in 2009. The piece also talks about similar successful experiments, for instance at Justus von Liebig’s laboratory in Germany or Ivan Pavlov’s laboratory in Russia and places a significant share of the productivity in successful labs on the shoulders of their leaders. The MRC’s leaders led less and interacted more. Tea was a daily tradition and Nobel Laureates sat at the same table with graduate students and postdocs during lunch. Everyone was encouraged to speak up and no one was afraid to ask what could be perceived as a stupid question; Tom Steitz who was awarded a prize for work on the ribosome remembers a meeting where director Max Perutz asked about the difference between prokaryotes and eukaryotes. The ideal leader directed less vertically and more horizontally.
Some of the Nobel Laureates at the MRC

A similar tradition was carried out in many other outstanding institutes producing famous scientists; these included the Institute for Advanced Study at Princeton (where Robert Oppenheimer used to say that “tea is where we explain to each other what we don’t understand”), Niels Bohr’s institute in Copenhagen which nurtured the founders of quantum mechanics and the forerunner of the MRC, Ernest Rutherford and Lawrence Bragg’s Cavendish Laboratories which discovered both the neutron and the structure of DNA. The same principle applied to industrial labs like Bell Labs and IBM; as Jon Gertner’s book on Bell Labs chronicles, Bell’s first director Mervin Kelly gave his scientists the same freedom. This freedom manifested itself even in the physical layout of the buildings which featured movable panels that allowed experimental and theoretical sanctums to connect. And it goes without saying that Kelly and most other successful directors were world class scientists themselves or at least people with a considerable scientific background. Contrast that with much of today’s corporate research enterprise where scientific leaders at the top have been replaced with lawyers and MBAs.
It’s also worth noting that these scientific leaders never made the mistake of equating quality with quantity; Rutherford’s lab even had a rule that forbade work after 6 PM except in rare cases. There’s a huge lesson there for professors and departments who insist that their students spend 12 or 14 hour days at the bench. As history has adequately demonstrated, it’s very much possible to work a productive 9 AM – 6 PM workday and still achieve significant results, and I have been told this is the way it still largely works in countries like Germany. The key lies in culture, collaboration and focus, not raw work hours. It’s really not that hard to understand that the best results arise when scientists are supplied with a general overarching plan but are otherwise left free to work out their own details for implementing it. And often the best short-term research is long-term research.
A friend of mine tells the story of her father who was working at a well-known government institution in the US. He quit when they started circulating forms that asked the scientists what they thought they would discover next year. “How the hell should I know what I am going to discover next year?”, wrote my friend’s father on the form before he stormed out.
Image links: 1, 2 

Post first published on the Scientific American blog network.

ChemCoach Carnival: What I do

I am late to the party, but SeeArrOh's ChemCoach Carnival has given me a chance to indulge in some narcissistic self-promotion. There many great entires on his blog so you should take a look. Here's my pitch.


Your current job.

I am an organic chemist turned molecular modeler at a small biotech startup in Cambridge, MA. I spend as much time looking at synthetic strategies, building block procurement, target selection and assays as I spend building models. I also spend a lot of time thinking about how my work fits within the broader boundaries of science.

What you do in a standard "work day."

As a lot of others scientists on this thread have emphasized, one of the great things about our job is that there is no “standard work day”. I am the lone modeler in a small startup so that requires me to wear several hats. I am as involved in discussing synthesis and assays as I am in docking small molecules to proteins or running molecular dynamics simulations. In addition I also need to occasionally look up building block availablity, talk to database and informatics specialists and arrange for presentations from outside vendors. The point is that in drug discovery and especially in a small outfit, you must be adaptable and be able to accomplish multiple, diverse tasks. This kind of capability makes you a valued member of the team, especially in a small company where your voice will be heard by everyone, from the intern to the CEO. It’s also a terrific learning experience in general.

What kind of schooling / training / experience helped you get there?

I have a doctorate in organic chemistry, although frankly that is just the means to an end. I switched from synthesis to modeling because I was clumsy in the lab and because I was interested in many different fields of science. I don’t regret my choice at all. Modeling allowed me to indulge interests in physics, chemistry, computer science and biology. I would say that if you have diverse scientific interests, modeling and simulation in a general sense would excellent career choices for you. If you are planning for a career in drug discovery or biotechnology, I would encourage you to soak up as much knowledge from diverse fields of chemistry and biology as possible. You won’t regret it.

This would also be the place for me to sneak in my favorite pitch regarding the history and philosophy of science. A simple piece of advice: study it. Science is done by fascinating human beings with all their flaws and triumphs. Your experiments are not being done in a vacuum. Reading up on the history of your discipline will give you the feeling of participating in a grand, unbroken thread of discovery going back to the Greeks. Even if you may not be a world-famous scientist or are not doing earth-shattering research, the simple fact that you are exploring the same laws of physics and chemistry that world-famous scientists once did will put you in their league and inspire a feeling of kinship. Studying the history of science will convince you that there are many who empathize and who have shared the same sense of despair and triumph that you do. Study the history of science, and you will know that you are not alone.

How does chemistry inform your work?

It is all-pervasive in my work. When I say I am a “molecular modeler”, I mean that in the broadest sense of the term. For me all of chemistry is largely about models, whether the models consist of structures scribbled on a hood or three-dimensional protein images built on a computer screen. A lot of people think computation in drug discovery is all about building regression models and writing fancy algorithms. But what it’s really about is data interpretation, and pretty much all this data is chemical. I cannot stress how important it is for a molecular modeler to understand chemistry, especially organic and physical chemistry. What has turned out to be an intractable problem has often proved amenable to a solution found in the principles of basic organic chemistry. In addition you have to have a real feel for structure-activity relationships and the basic physiochemical properties of functional groups. Useful numbers from thermodynamics and kinetics should ideally roll off your tongue like French verbs. A knowledge of statistics is also important. My background in organic chemistry is much more important than any facility with programming or knowledge of particular software that I may have picked up on the way. Those things you can learn, but the bedrock of your work will always be chemistry, even when it's operating behind the scenes.

Finally, a unique, interesting, or funny anecdote about your career*

Well, when I said I was clumsy in the lab I was thinking about the time I actually dropped a rotavap on the floor and broke it. My advisor, a generous man, said that maybe I was not quite cut out for working in the lab. It was the only time in my life that an embarrassing accident gently pointed out by a wise future advisor has fortuitously decided the trajectory of my career.

In which the Discovery Institute mocks me and reveals its ignorance...again.

You must be doing something useful if the Discovery Institute, that bastion of intelligent design propaganda, devotes an entire post to your article.

This time it was the piece on junk DNA that I wrote for Scientific American. Here's what the DI folks had to say:


Darwinian "Science" in Action


Evolution News & Views  October 9, 2012 5:53 AM | Permalink

Someone forgot to put Scientific American blogger Ashutosh Jogalekar on the list to get the memo on massaging the ENCODE results. Darwinists used to say a genome scattered with junk is just what you'd expect from natural selection. Now they say the reverse, that a much more fully functional genome is just what you'd expect. (See here for David Klinghoffer's note on Richard Dawkins's remarkable change of heart.)
But in the immediate wake of ENCODE, poor Jogalekar was still carrying on with the old talking point ("Three reasons why junk DNA makes evolutionary sense").
We think his third paragraph is most revealing:
But what I found astonishing was why it's so hard for people to accept that much of DNA must indeed be junk. Even to someone like me who is not an expert, the existence of junk DNA appeared perfectly normal. I think that junk DNA shouldn't shock us at all if we accept the standard evolutionary picture.
In other words, because Darwinism is true, "much of DNA must indeed be junk." Theory trumps evidence. That's Darwinian "science" for you.

As usual, the DI's interpretation is chock full of misleading statements. Let's address the objections in short order:

1. Yes, I was not on the ENCODE memo because the whole point that people like me, Larry Moran and Ryan Gregory were making is that the ENCODE results misrepresented the lack of significance of junk DNA by having their own, very liberal, definition of "functional" DNA sequences. Several posts criticized the widely disseminated impression provided by ENCODE that "80%" of DNA was functional. The DI of course jumped on this bandwagon with alacrity since it fit like a jigsaw puzzle piece into their worldview that most or all of the human genome had to be "designed". As many commentators mentioned, the 80% quip was a PR disaster.

2. The "old talking point" is old precisely because it fits well into standard evolutionary theory. The DI wants to make it sound like scientists were for junk DNA before they were against it before they were for it again. This of course proves that scientists are a confused lot who are not sure about anything...

The truth of course is that "junk DNA" was always a misnomer since we did not know what function, if any, the sequences of DNA regarded as "junk" would turn out to have. Now some of them (but a small percentage) did indeed turn out to be functional in the true sense of being coding or regulatory elements. But the fact is that many of them are still non-functional by these same definitions. 

What scientists were saying is that some DNA which was regarded as "junk" might turn out to be functional, and in fact it has been found to be so. However, there is no reason - based on standard evolutionary interpretations which I explored in my post - to assume that most DNA would have a function. Will we find function for some more DNA in the future? Absolutely. Does that still mean that most DNA is functional? Of course not. Thus, contrary to what the DI would have us think, believing that some junk DNA would turn out to be functional but also believing that most DNA might still be predictably "junk" are not opposed viewpoints. The DI would have us believe that they are and this then becomes a convenient vehicle for them to insinuate that scientists are not sure of anything.

The last statement is just a gross misunderstanding of the scientific method:

In other words, because Darwinism is true, "much of DNA must indeed be junk." Theory trumps evidence. That's Darwinian "science" for you.

No, the accurate way to say this is that "evidence supports theory". The DI wants to give the impression that we "Darwinists" used two sets of evidence, one contradictory to the other, to support our pet theory. But as I have indicated, it's a straw man to proclaim that these two sets are contradictory. Both pieces of evidence are entirely consistent with a standard evolutionary interpretation in which some junk DNA does turn out to be functional without providing any reason to believe that most junk DNA would also be the same.

It's not that hard to understand. At best the confusion is a result of confusing nomenclature and bad PR, not a failure of evolutionary theory that the DI would perpetually have us buy into.

When satire hits home

Fiction indeed mirrors reality more than we would ever want it to...

From The Onion:


Latest Study Finds Cancer Cells Now Cruelly Mocking Researchers


ROCHESTER, MN—Stating that cancer cells are now “laughing in our fucking faces,” a new Mayo Clinic study with widespread implications for the treatment and potential cure of the disease has found that the malignant growths have begun cruelly mocking researchers. 

The findings—published this week in a rambling, expletive-laden 8,000-word article in The Journal Of The American Medical Association—provides the strongest evidence yet that abnormal cells targeted with cutting-edge cancer treatments are basically flipping off scientists left and right, and get a huge kick out of making oncologists feel like a bunch of bumbling dipshit chumps...
..."You can almost hear them cackling at us while they spread to the lymph nodes,” he added.
According to the study, researchers now have a much better sense of the molecular and cellular basis of tumor growth, including the ingrained sense of entitlement that reportedly drives cancer cells to grow irregularly until they become one big fuck-you to scientists.
The report confirmed that while all types of carcinomas are beginning to make researchers feel like garbage, myeloma cancer cells in particular think they’re God’s gift just because they’re resistant to the frontline drug Velcade.
Researchers found that in addition to those toxic cells, basal cell carcinomas also get a “certain sick joy out of smacking researchers around like a bunch of little bitches.”
“Several years ago, when you looked at cancer cells under a microscope, they weren’t such huge jerks,” said Dr. Karen Phillips, an oncologist at Johns Hopkins Medical Center. “But now they are playing with us—taunting us even. For example, one minute, ovarian granulosa cell tumors and other stromal malignancies are being successfully destroyed with a cisplatin and etoposide combination chemotherapy. But the next minute, those shit-eaters are overexpressing the BRCA1 locus protein and triggering the expression of the antiapoptotic protein survivin, thus protecting ovarian cells from cisplatin-induced survivin down-regulation and making them completely chemo-resistant.”

A chestnut so old, it's started stinking

Both Derek and SeeArrOh have nicely weighed in on this Washington Post letter by a disgruntled parent who is demanding to know why his son should be "forced" to study chemistry in high school. He then lists a number of arguments usually offered in favor of teaching and learning chemistry and proceeds to what he thinks are cogent rejoinders. This one in particular sent a giant bee through my bonnet:

Chemistry will teach him analytical skills that he can apply to other fields.

Great. So will a hundred other possible subjects that will be less painful and potentially even more interesting to him. An experimental physicist recently told me that at this phase in chemistry instruction “it’s all about memorization anyway.” There will be no other phases in chemistry instruction for my son. He will forget everything he “learned” a week after the class is over. I can’t remember a thing, and I was a pretty good chemistry student.

Ah, the "math and physics need good problem solving skills while chemistry and biology need a good memory" chestnut again, and SeeArrOh touches on this. I am hazarding a guess that this experimental physicist was jealous of chemists; I am tempted to send a few beakers flying through his office window. I was exposed adequately to this fallacy myself; when I was in high school, apparently all the future engineers were supposed to study physics and math to hone their analytical skills while the future doctors were supposed to study chemistry and biology, since "medicine is all about memorization too". This was nonsense. Chemistry is as useful for future engineers as math is for future doctors.

Obviously our schools are still not doing a good job of driving home the analytical nature of chemical science. Try to memorize every reaction in an organic chemistry textbook and you will indeed not remember any of it within a few months. But try instead to learn a few unifying principles like syn-anti addition, pkA, stereochemistry, acid-base chemistry and resonance and you can make sense of a vast landscape of chemistry which you will likely remember. The best textbooks like the one by Clayden et al. indeed emphasize this unified approach. In addition, learning the subject this way will make chemistry much less painful than memorizing it. 

It's very likely that the letter writer's high school teacher made chemistry all about memorization; if that had been the case then it might have been easy to be good at chemistry in the short-term without really understanding most of it. Unfortunately much of chemistry and biology is still stuck - if not by content, by its mental makeup and by the attitude of its teachers- in the nineteenth century where there was no structural theory and no molecular biology and therefore these sciences did appear like a set of disconnected facts to be memorized. That's also why chemistry makes a convenient target. Math and physics are much more obviously about analytical and logical thinking whereas biology is much more easily seen as essential for things like medicine. Chemistry as usual is the middle child, the one everyone likes to treat with benign neglect. But the fact is that the twentieth century saw both chemistry and biology elevated to the status of conceptual sciences, perhaps not as pristinely analytical as math but enough to be able to take a completely logical approach to the way in which they are taught.

Derek and SeeArrOh cover the other objections thoroughly. Physics, chemistry, biology and math are all part of the world we inhabit. I cannot see how omitting any of these from the school curriculum (along with history, politics, economics and literature) could contribute to an informed citizenry. The writer probably makes a good case that a high school shouldn't "force" students to take chemistry, but that hardly detracts from chemistry's intrinsic value value.

Come on Mr. Bernstein, you should at least have your son take chemistry so he can recognize all those dangerous "chemicals" in food products...